Apricus Biosciences Inc. (Nasdaq: APRI) received approval for its erectile dysfunction treatment Vitaros through the European Decentralized Procedure. The stock price rose 24 cents to $2.80.
DCP Approves Apricus Biosciences' ED Treatment
June 10, 2013 at 13:22 PM EDT
